All In Biotech

Drug Trial Radar · NCT02797821

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

A Phase 2a, Randomized, Multicenter, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia

Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Jun 6, 2016

Primary completion

Jun 21, 2017

Study completion Jun 21, 2017

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of asfotase alfa in adult participants with pediatric-onset HPP.

Conditions

  • Hypophosphatasia

Interventions

  • Asfotase alfaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change In Plasma PPi From Baseline To Pre-3rd Dose At Week 9Time frame: Baseline to Week 9

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Shriners Hospitals for Children

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Vanderbilt Medical Center Endocrinology

    Nashville, Tennessee

  • University of Würzburg

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.